Health and Quality of Life Outcomes 2009, 7:91 http://www.hqlo.com/content/7/1/91
Page 7 of 8
(page number not for citation purposes)
agents. Whether the MID estimates for HFS scores found
in this study are applicable to different types of diabetes
patients, countries, and cultures should be subject of
Conflict of interests statement
TS was on a research fellowship sponsored by Merck &
Co., Inc, by the time the article was written. LGF has been
working under a consultancy agreement for Merck & Co.,
Inc. LGF has also worked under consultancy agreements
or received research grants from Abbott Diabetes Care,
Abbott Labs. KJK and CA are employees of Merck & Co.,
KJK conceived the idea to write this paper. TS analyzed the
data and drafted the first version of the manuscript. All
authors contributed to the conception and design of the
study, to interpreting the data, and to writing the manu-
script. All authors read and approved the final manu-
1. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR: Glyc-
emic control continues to deteriorate after sulfonylureas are
added to metformin among patients with type 2 diabetes.
Diabetes Care 2005, 28:995-1000.
2. Nathan DM, Buse JB, Mayer BD, Heine RJ, Holman RR, Sherwin R, et
al.: Management of hyperglycemia in type 2 diabetes: a con-
sensus algorithm for the initiation and adjustment of ther-
apy. Diabetes Care 2006, 29:1963-1972.
3. Cook MN, Girman CJ, Stein PP, Alexander CM: Initial mono-
therapy with either metformin or sulphonylureas often fails
to achieve or maintain current glycaemic goals in patients
with type 2 diabetes in UK primary care. Diabet Med 2007,
4. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld
M, et al.: Rosiglitazone RECORD study: glucose control out-
comes at 18 months. Diabet Med 2007, 24:626-634.
5. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Tan MH,
Hanefeld M: Long-term efficacy and tolerability of add-on
pioglitazone therapy to failing monotherapy compared with
addition of gliclazide or metformin in patients with type 2
diabetes. Diabetologia 2005, 48:1093-1104.
6. Chelliah A, Burke MR: Hypoglycemia in elderly patients with
diabetes mellitus. Drugs & Aging 2004, 21:511-530.
7. Davis S, Alonso MD: Hypoglycemia as a barrier to glycemic
control. J Diabetes Complications 2004, 18:60-68.
8. Amiel SA, Dixon T, Mann R, Jameson K: Hypoglycaemia in type 2
diabetes. Diabet Med 2008, 25:245-254.
9. Banarer S, Cryer PE: Gypoglycemia in type 2 diabetes. The Med-
ical Clinics of North America 2004, 88:1107-1116.
10. Boyle PJ, Zrebiec J: Physiological and behavioral aspects of gly-
cemic control and hypoglycemia in diabetes. South Med J 2007,
11. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoff-
mann RM: Hypoglycemia in stable, insulin-treated verterans
with type 2 diabetes, a retrospective study of 1662 episodes.
J Diabetes Complications 2005, 19:10-17.
12. Zammitt NN, Frier BM: Hypoglycemia in type 2 diabetes. Dia-
betes Care 2005, 28:2948-2961.
13. Frier BM: Hypoglycemia and cognitive function in diabetes. Int
J Clin Pract 2001, S123:30-37.
14. Rosenthal JM, Amiel SA, Yágüez L, Bullmore E, Hopkins D, Evans M,
et al.: The effect of acute hypoglycemia on brain function and
activation. Diabetes 2001, 50:1618-1626.
15. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV:
Hypoglycemic episodes and risk of dementia in older
patients with type 2 diabetes mellitus. JAMA 2009,
16. American Diabetes Association Workgroup on Hypoglycemia:
Defining and reporting hypoglycemia in diabetes. Diabetes
Care 2005, 28:1245-1249.
17. Boyle PJ, Zrebiec J: Management of diabetes-related hypoglyc-
emia. South Med J 2007, 100:183-194.
18. Nattrass M, Lauritzen T: Review of prandial glucose regulation
with reaglinide: a solution to the problem of hyoglycemia in
the treatment of type 2 diabetes. Int J Obes 2000, 24:21-31.
19. Gonder-Frederick L, Cox DJ, Clarke W, Julian D: Blood glucose
awareness training. In Psychology in diabetes Care Edited by: Snoek
FJ, Skinner TC. New York: Wiley; 2000:169-206.
20. Cox DJ, Gonder-Frederick L, Polonsky W, Schlundt D, Kovatchev B,
Clarke W: Blood glucose awareness training (BGAT-2): Long-
term benefits. Diabetes Care 2001, 24:638-42.
21. Johnson JA, Kotovych M, Ryan EA, Shapiro AM: Reduced fear of
hypoglycemia in successful islet transplantation. Diabetes Care
22. Jaeschke R, Singer J, Guyatt DH: Measurement of health status:
ascertaining the minimal clinically important difference. Con-
trol Clin Trials 1989, 10:407-415.
23. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, the clin-
ical significance consensus meeting group: Methods to explain the
clinical significance of health status measures. Mayo Clin Proc
24. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al.:
Validation of a general measure of treatment satisfaction,
the Treatment Satisfaction Questionaire for Medication
(TSQM), using a national panel study of chronic disease.
Health and Quality of Life Outcomes 2004, 2:1-13.
25. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J:
Fear of hypoglycemia: quantification, validation and utiliza-
tion. Diabetes Care 1987, 10:617-621.
26. Irvine A, Cox DJ, Gonder-Frederick L: The Fear of hypoglycemia
scale. In Handbook of psychology and diabetes: a guide to psychological
measurement and diabetes research and practice Edited by: Bradley C.
Langhorne: Hardwood Academia Publishing; 1994:133-158.
27. Revicki DA, Hays RD, Cella D, Sloan JA: Recommended methods
for determining responsiveness and minimally important dif-
ferences for patient-reported outcomes. J Clin Epidemiol 2008,
28. U.S. Department of Health and Human Services FDA Center for Drug
Evaluation and Research, U.S. Department of Health and Human Serv-
ices FDA Center for Biologics Evaluation and Research, U.S. Depart-
ment of Health and Human Services FDA Center for Devices and
Radiological Health: Guidance for industry: patient-reported
outcome measures: use in medical product development to
support labelling claims. Health and Quality of Life Outcomes 2006,
29. Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, et al.:
Minimally important differences were estimated for the
Functional Assessment of Cancer Therapy-Colorectal
(FACT-C) instrument using a combination of distribution-
and anchor-based approaches. J Clin Epidemiol 2005,
30. Beaton D, Bombardier C, Katz JN, Wright JG, Wells GA, Boers M, et
al.: Looking for important change/differences in studies of
responsiveness. The Journal of Rheumatology 2001, 28:
31. Walters SJ, Brazier JE: Comparison of the minimally important
difference for two health state utility measures: EQ-5D and
SF-6d. Qual Life Res 2005, 14:1523-1532.
32. Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA:
Minimum important difference between patients with rheu-
matoid arthitis: the patient's perspective. The Journal of Rheu-
matology 1993, 20:557-560.
33. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et
al.: Frequency of severe hypoglycemia requiring emergency
treatment in type 1 and type 2 diabetes. Diabetes Care 2003,
34. Lydick E, Epstein R: Interpretation of quality of life changes.
Qual Life Res 1993, 2:221-6.
35. Marquis P, Chassany O, Abetz L: A comprehensive strategy for
the interpretation of quality-of-life data based existing meth-
ods. Value in Health 2004, 7:93-104.